Marharyta Khaustova

Marharyta Khaustova

II Medical Department, Kharkiv National Medical University, Kharkiv, Kharkivs’ka Oblast’, Ukraine
orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2026 in American Journal of Clinical Oncology
Verified
Journal Article
Closed access
LTLance G. Tolentino
Lance G. Tolentino
Marharyta KhaustovaMarharyta Khaustova
Marharyta Khaustova
RAReham Zare Alrwaitey
Reham Zare Alrwaitey
ACAsiya S. Chintala
Asiya S. Chintala
DBDebasrita Baidya
Debasrita Baidya
MAMuhammad Ayyan
Muhammad Ayyan
Objectives: Sacituzumab govitecan (SG), a Trop-2-directed antibody-drug conjugate, has demonstrated clinical activity in HER2-negative breast cancer. Our meta-analysis aimed to evaluate the efficacy and safety of SG compared with standard chemotherapy in patients with breast cancer. Methods: We conducted a comprehensive literature search across multiple databases for RCTs comparing SG with standard treatment in patients with breast cancer. The primary outcomes were progression-free survival (PFS) and overall survival (OS). Secondary outcomes included objective response rate (ORR), clinical benefit rate (CBR), disease control measures, and treatment-related adverse events. Hazard ratios (HRs), mean differences (MDs), and risk ratios (RRs) with 95% CIs were pooled using a random-effects model. Results: Six RCTs encompassing 2481 patients were included. SG significantly improved PFS ( HR =0.59), OS ( HR =0.63), and ORR ( RR =1.64) compared with chemotherapy. CBR was also significantly higher with SG ( RR =1.89), and the rate of progressive disease was significantly lower ( RR =0.62). Overall treatment-related adverse events were similar in both groups ( RR =1.05). Neutropenia and diarrhea were significantly more frequent in the SG group. Conclusions: Our meta-analysis shows that sacituzumab govitecan significantly improves PFS, OS, and ORR compared with standard chemotherapy in patients with HER2-negative breast cancer. Although associated with higher rates of neutropenia and diarrhea, its overall safety profile remains manageable. These results reinforce the role of SG as an effective treatment option for both metastatic TNBC and HR+/HER2− breast cancer and support its continued evaluation in earlier treatment settings and combination strategies, including immunotherapy.

21 September 2026 in Cancers
Verified
Journal Article
Open access
PDF file
Marharyta KhaustovaMarharyta Khaustova
Marharyta Khaustova
ELElisabetta Liberanome
Elisabetta Liberanome
AGAnnamaria De Giorgi
Annamaria De Giorgi
LGLuigi Pio Guerrera
Luigi Pio Guerrera
FPfausto petrelli
fausto petrelli
MGMichele Ghidini
Michele Ghidini
Background/Objectives: Standard guidelines for treating locally advanced and metastatic gastroesophageal cancer (GEC) involve combination regimens of chemotherapy and immunotherapy. Patient eligibility for these treatments is primarily guided by the programmed cell death ligand 1 (PD-L1) combined positive score (CPS). This approach assumes that a single baseline biopsy accurately reflects a stable, tumor-wide PD-L1 status, an assumption increasingly challenged by spatial and temporal heterogeneity. This systematic review aims to synthesize existing data on PD-L1 expression dynamics before and after systemic therapy in GEC, and to evaluate whether these changes differ between neoadjuvant and metastatic settings. Methods: We systematically searched PubMed/MEDLINE (up to May 2026) for studies reporting paired pre- and post-treatment PD-L1 status in gastric and gastroesophageal junction cancers. This systematic review was conducted in accordance with the PRISMA 2020 guidelines. Narrative synthesis and qualitative data transformation were structured following the Synthesis Without Meta-analysis (SWiM) reporting framework. Study-level risk of bias was assessed using the Newcastle-Ottawa Scale (NOS). Results: Eleven studies were included in this systematic review, stratified into neoadjuvant (n = 6) and metastatic (n = 5) settings. Our findings suggest that changes in PD-L1 expression in gastroesophageal cancer depend heavily on the clinical setting. Specifically, an upward trend in post-treatment PD-L1 expression was evident in the neoadjuvant setting, with 5 of 6 studies reporting a prevalence of PD-L1 gain ranging from 6.3% to 33.3%. Conversely, PD-L1 downregulation was consistently reported across all metastatic studies, with loss rates ranging from 19.3% to 44.4%. Conclusions: PD-L1 status in gastroesophageal cancer changes dynamically after treatment. These findings highlight the limitations of relying on archival tissue and support the use of repeat biopsies to track evolving tumor phenotypes. This study is primarily limited by small sample sizes of paired biopsies, technical heterogeneity in PD-L1 scoring and treatment regimens, potential publication bias, and the lack of prospective registration.